ALCLS.PA stock fell to €2.99 in after-hours trade on 19 Mar 2026 after Cellectis S.A. published its earnings update. We saw an intraday decline of -4.17% on volume of 245,414 shares as investors parsed clinical progress and cash metrics. The company reports on EURONEXT for the Europe market and we are watching EPS -0.28 and guidance signals that could drive near-term volatility.
Earnings recap and market reaction: ALCLS.PA stock
Cellectis released results tied to its clinical timeline on 19 Mar 2026 and the immediate market response pushed the share price to €2.99, down -4.17% from the prior close. Trading volume was 245,414 versus an average of 246,358, showing typical investor attention but no large directional washout.
Valuation and balance sheet snapshot for ALCLS.PA stock
On standard metrics Cellectis shows a negative PE of -11.00 and EPS of -0.28, with price-to-sales 3.40 and price-to-book 3.53. The company holds €1.90 cash per share and a current ratio of 1.49, while debt-to-equity sits at 0.92, indicating modest leverage for a clinical-stage biotech.
Clinical pipeline and catalysts affecting ALCLS.PA stock
Cellectis remains a clinical-stage immuno-oncology specialist with programs such as UCART19, ALLO-501/501A and UCART123 that are key value drivers. Upcoming trial readouts and partnership updates with institutions like M.D. Anderson will be the primary catalysts for the stock in the next 6 to 12 months.
Technical setup and trading signals for ALCLS.PA stock
Short-term technicals show momentum weak but not collapsed: RSI 40.63, MACD histogram -0.02 and Bollinger middle band at €3.32. The stock trades below its 50-day average €3.40 but near the 200-day average €2.96, which sets a technical support cluster around €2.96 and initial resistance in the €3.60–€3.70 band.
Meyka AI rates ALCLS.PA with a score out of 100 and forecast
Meyka AI rates ALCLS.PA with a score out of 100: 69.05 / 100 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month base price of €5.60, a monthly target of €3.30, and a 3-year projection of €9.48, all model-based projections and not guarantees.
Risks, rating updates and analyst context for ALCLS.PA stock
Key risks include clinical trial setbacks, high R&D spend (research and development is 119.50% of revenue TTM) and a recent company rating of D+ (dated 18 Mar 2026) flagging near-term downside. We track cash runway, patient enrollment updates and partnership milestones as decisive risk controls.
Final Thoughts
Key takeaways: ALCLS.PA stock opened after hours at €2.99 on 19 Mar 2026 with a -4.17% move as the market digested clinical and financial details. Fundamentals show negative earnings and a high R&D intensity but reasonable liquidity with €1.90 cash per share and a current ratio 1.49. Meyka AI’s forecast model projects a 12-month base price of €5.60, implying an upside of 87.29% vs the current price €2.99, with a conservative near-term target of €3.80 (+27.09%) and a 3-year projection of €9.48 (+217.24%). These forecasts are model-based projections and not guarantees. We recommend monitoring upcoming trial readouts, cash runway commentary, and any partnership announcements. For live quotes and deeper screening see Meyka’s real-time page for ALCLS.PA and cross-check regulatory filings and clinical updates before trading decisions.
FAQs
What drove ALCLS.PA stock lower after hours on 19 Mar 2026?
The after-hours dip to €2.99 followed the earnings update and investor caution around clinical timelines and cash burn. Market reaction reflected negative EPS -0.28 and ongoing R&D intensity rather than a single pricing shock.
What is Meyka AI’s 12-month forecast for ALCLS.PA stock?
Meyka AI’s forecast model projects a 12-month base price of €5.60 for ALCLS.PA stock, implying an 87.29% upside from €2.99 today. Forecasts are model projections and not guarantees.
Which metrics should I watch for ALCLS.PA stock after earnings?
Focus on cash runway, clinical enrollment milestones for UCART programs, R&D burn, and guidance language. Watch EPS trends and liquidity ratios such as cash per share €1.90 and current ratio 1.49.
How does sector performance affect ALCLS.PA stock outlook?
As a biotechnology healthcare name listed on EURONEXT, ALCLS.PA stock is sensitive to sector flows and risk appetite for clinical-stage companies; biotech sentiment swings can amplify price moves regardless of company-specific news.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)